Home / Pharmaceuticals / Acquired Hemophilia Treatment Market By Type Of Therapeutics (Traditional Therapy, Advanced Therapy) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

Acquired Hemophilia Treatment Market By Type Of Therapeutics (Traditional Therapy, Advanced Therapy) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

Published: Jan 2017 | Report Code: 57894-01-17

According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Medical practitioners suggest that, acquired hemophilia can potentially cause life-threatening bleeding complications in severe cases and in around 50% of cases, there is an identifiable underlying clinical condition; in the other 50% no cause is known i.e. idiopathic.

The report titled “Global Acquired Hemophilia Treatment Market - Growth Future Prospects and Competitive Analysis, 2016–2023” offers strategic insights into the overall acquired hemophilia treatment market along with the market size and estimates for the duration 2016 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of therapeutics, and different geographical region. The therapeutic type segment studied for analyzing the overall acquired hemophilia treatment two major categories such as traditional therapies and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment and immunomodulatory treatment. The advanced therapies is further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in acquired hemophilia treatment market, attractive investment proposition market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the global acquired hemophilia treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2013-2023. Market growth rates for the forecast period 2016-2023 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global acquired hemophilia treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global acquired hemophilia treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global acquired hemophilia treatment market. In-depth competitive environment analysis and historical years (2013 & 2014) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global acquired hemophilia treatment market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.

Acquired Hemophilia Treatment

Chapter 1 Preface 8
1.1 Report Description 8
1.1.1 Purpose of the Report 8
1.1.2 Target Audience 8
1.1.3 USP and Key Offerings 8
1.2 Research Scope 9
1.3 Research Methodology 10
1.3.1 Phase I – Secondary Research 10
1.3.2 Phase II – Primary Research 11
1.3.3 Phase III – Expert Panel Review 11
1.3.4 Assumptions 12

Chapter 2 Executive Summary 13
2.1 Acquired Hemophilia Treatment Market Portraiture 13
2.2 Acquired Hemophilia Treatment Market, by Therapeutic Type, 2015 (US$ Mn) 14
2.3 Acquired Hemophilia Treatment Market, by Geography, 2015 (Value %) 15

Chapter 3 Global Acquired Hemophilia Treatment Market Analysis 16
3.1 Global Acquired Hemophilia Treatment Market Overview 16
3.2 Prevalence of Acquired Hemophilia 17
3.3 Market Dynamics 18
3.3.1 Market Drivers 18
3.3.1.1 Rise in Geriatric Population 18
3.3.1.2 Growing Demand for Prophylaxis Strategies 19
3.3.2 Challenges 20
3.3.2.1 Availability and Accessibility Constraints 20
3.3.3 Opportunities 21
3.4 Attractive Investment Proposition 21
3.5 Competitive Analysis: Global Acquired Hemophilia Treatment Market, 2015 (Value %) 22

Chapter 4 Global Acquired Hemophilia Treatment Market Analysis, By Type of Therapeutics 24
4.1 Preface 24
4.2 Traditional Therapy 24
4.3 Advanced Therapy 27
4.3.1 Desmopressin (DDAVP) 28
4.3.2 Recombinant Activated Factor VII/NovoSeven RT 30
4.3.3 Recombinant Porcine Factor VIII/Obizur 31
4.3.4 Activated Prothrombin Complex Concentrate (aPCC)/FEIBA 32

Chapter 5 Global Acquired Hemophilia Treatment Market, By Geography 34
5.1 Preface 34
5.1.1 Global Acquired Hemophilia Treatment Market, by Geography, 2014 - 2023 34
5.2 North America (U.S. & Canada) 35
5.3 Europe (U.K., Germany & Rest of Europe) 36
5.4 Asia Pacific (China, Japan, Singapore, South Korea and Rest of APAC) 38
5.5 Latin America (Mexico, Brazil and Rest of LATAM) 39
5.6 Middle East and Africa 40

Chapter 6 Company Profiles 42
6.1 Baxalta, Inc 42
6.2 Baxter Healthcare Corporation 43
6.3 Bristol-Myers Squibb 44
6.4 Genentech, Inc. 45
6.5 Novo Nordisk A/S 46
6.6 Ferring B.V. 47
6.7 Sanofi SA 49

List Of Table :

TABLE 1 Global Acquired Hemophilia Treatment Market, By Therapeutic Type (US$ Mn), 2013 - 2023 24
TABLE 2 Global Acquired Hemophilia Treatment Market, By Traditional Therapy (US$ Mn), 2013 - 2023 25
TABLE 3 Global Acquired Hemophilia Treatment Market, By Advanced Therapy (US$ Mn), 2013 - 2023 28
TABLE 4 Global Acquired Hemophilia Treatment Market (US$ Mn), by Geography, 2013 – 2023 34
TABLE 5 North America Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2013 – 2023 36
TABLE 6 Europe Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2013 – 2023 37
TABLE 7 Asia-Pacific Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2013 – 2023 38
TABLE 8 Baxalta, Inc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage) 42
TABLE 9 Baxter Healthcare Corporation: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 43
TABLE 10 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 44
TABLE 11 Genentech, Inc.: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 45
TABLE 12 Novo Nordisk A/S: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 46
TABLE 13 Ferring B.V.: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 47
TABLE 14 Sanofi SA: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 49

List Of Figure :

FIG. 1 Acquired Hemophilia Treatment Market, Research Methodology 10
FIG. 2 Acquired Hemophilia Treatment Market, by Type of Device, 2015 (US$ Mn) 14
FIG. 3 Acquired Hemophilia Treatment Market, by Geography, 2015 (Value %) 15
FIG. 4 Attractive Investment Proposition 22
FIG. 5 Competitive Analysis: Global Acquired Hemophilia Treatment Market, 2015 (Value %) 23
FIG. 6 Desmopressin (DDAVP) Market (US$ Mn), 2013-2023 29
FIG. 7 Recombinant Activated Factor VII/NovoSeven RT Market (US$ Mn), 2013-2023 30
FIG. 8 Recombinant Porcine Factor VII/Obizur Market (US$ Mn), 2013-2023 31
FIG. 9 Activated Prothrombin Complex Concentrate (aPCC)/FEIBA Market (US$ Mn), 2013-2023 32
FIG. 10 Latin America (Mexico, Brazil and Rest of LATAM) Acquired Hemophilia Treatment Market (US$ Mn), 2013 – 2023 39
FIG. 11 Middle East & Africa Acquired Hemophilia Treatment Market (US$ Mn), 2013 – 2023 41

Based on the type of therapeutics, the acquired hemophilia treatment market is segmented into:

  • Traditional Therapies
    • Steroid Treatment
    • Cytotoxic Treatment
    • Immunomodulatory Treatment
  • Advanced Therapies
    • Desmopressin
    • Recombinant Activated Factor VII/NovoSeven
    • Recombinant Activated Factor VIII/Obizur
    • Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA

According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Treatment strategies that are applied against acquired hemophilia are based on two major objectives. The primary objective is effective control of bleeding manifestations during acute bleeding episodes. The secondary and ultimate therapeutic objective is to eliminate the inhibitor and cure the disease. The acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories such as traditional therapies and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment and immunomodulatory treatment. The advanced therapies is further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA. The advanced therapies held the largest segment due to introduction of novel therapies for the treatment of acquired hemophilia. Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA held the largest market in 2015, due to better patient compliance, a prospective study reported that 100% patients had excellent hemostasis with FEIBA administration. However, the market for traditional therapies is expected to grow at a stable rate during for forecast period due to patent expiration of advanced therapy drug and introduction of breakthrough drugs that are currently in the clinical study.

Acquired Hemophilia Treatment

For the purpose of this study, the global acquired hemophilia treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Acquired Hemophilia Treatment

North America was observed as the largest market for acquired hemophilia treatment in the base year 2015. Constituted by regional markets of U.S. and Canada; North America is the clear leader in the global acquired hemophilia treatment market. North America dominated the market due to aging population, supportive government policies, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. In developed countries of U.S. and Canada, the network of hemophilia care centers is well set with domestic government support. The primary management option is evolved in developed countries with early treatment of bleeding episodes and quick home therapy. Asia Pacific was observed as the attractive market in acquired hemophilia treatment due to emerging healthcare infrastructure, high disposable income, transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients